Evidence map›Paper›PMID 38818800›Full record

ReviewTissue engineering. Part A2025

From Promise to Practice: Recent Growth in 30 Years of Tissue Engineering Commercialization.

Ryan B Felix, Amal Shabazz, William Pieper Holeman, Sarang Han, Matthew Wyble, Marylyn Uzoukwu, Lauren Audrey Gomes, Laena Nho, Mark Zachary Litman, Peter Hu and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Tissue engineering. Part A, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ryan B FelixFischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA.
Amal ShabazzFischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA.
William Pieper HolemanFischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA.
Sarang HanFischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA.
Matthew WybleFischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA.
Marylyn UzoukwuFischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA.
Lauren Audrey GomesFischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA.
Laena NhoFischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA.
Mark Zachary LitmanFischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA.
Peter HuDepartment of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
John P FisherFischell Department of Bioengineering, University of Maryland, College Park, Maryland, USA.

Funding

Training and Dissemination CoreP41EB023833 · NIBIB · UNIV OF MARYLAND, COLLEGE PARK · PI FISHER, JOHN P · 2017 to 2021
$6.2M
3D Bioprinted Nipple-Areolar Complex ImplantsR01HD112031 · NICHD · UNIV OF MARYLAND, COLLEGE PARK · PI John P Fisher · 2023 to 2026
$2.2M
Multiscale hydrogel biomaterials-enabled 3D modeling of cancer drug resistanceR01CA279815 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI Wenquan Ou · 2023 to 2026
$1.7M
NCI NIH HHS R01 CA279815NIBIB NIH HHS P41 EB023833NICHD NIH HHS R01 HD112031
6 · The paper itself

Abstract

This perspective, marking the 30th anniversary of the Tissue Engineering journal, discusses the exciting trends in the global commercialization of tissue engineering technology. Within a historical context, we present an evolution of challenges and a discussion of the last 5 years of global commercial successes and emerging market trends, highlighting the continued expansion of the field in the northeastern United States. This leads to an overview of the last 5 years' progress in clinical trials for tissue-engineered therapeutics, including an analysis of trends in success and failure. Finally, we provide a broad overview of preclinical research and a perspective on where the state-of-the-art lies on the horizon.

Indexed as

Tissue EngineeringAnimalsHistory, 20th CenturyHistory, 21st CenturyHumansbiomaterialsclinical translationcompanyindustrymarketregenerative medicinestem cellstissue engineering

Identifiers

PMID38818800
PMCPMC13626157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.